These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. FHIT oncosuppressor gene expression profile in human anal cancers. Zucchini C; Concu M; Martini F; Morelli C; Salfi N; Carinci P; Tognon M; Caramelli E Int J Biol Markers; 2007; 22(1):39-42. PubMed ID: 17393360 [TBL] [Abstract][Full Text] [Related]
24. Expression of abnormal transcripts of the FHIT (fragile histidine triad) gene in ovarian carcinoma. Mandai M; Konishi I; Kuroda H; Nanbu K; Matsushita K; Yura Y; Hamid AA; Mori T Eur J Cancer; 1998 Apr; 34(5):745-9. PubMed ID: 9713284 [TBL] [Abstract][Full Text] [Related]
25. fhit Alterations in endometrial carcinoma and hyperplasia. Ozaki K; Enomoto T; Yoshino K; Hongbo S; Nakamura T; Fujita M; Kuragaki C; Sakata M; Kurachi H; Murata Y Int J Cancer; 2000 Feb; 85(3):306-12. PubMed ID: 10652418 [TBL] [Abstract][Full Text] [Related]
26. Survivin overexpression in hepatocellular carcinoma is associated with p53 dysregulation. Kannangai R; Wang J; Liu QZ; Sahin F; Torbenson M Int J Gastrointest Cancer; 2005; 35(1):53-60. PubMed ID: 15722574 [TBL] [Abstract][Full Text] [Related]
27. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance. McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880 [TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic features and FHIT gene expression in sporadic colorectal adenocarcinomas. Luceri C; Guglielmi F; De Filippo C; Caderni G; Mini E; Biggeri A; Napoli C; Tonelli F; Cianchi F; Dolara P Scand J Gastroenterol; 2000 Jun; 35(6):637-41. PubMed ID: 10912665 [TBL] [Abstract][Full Text] [Related]
29. Decreased fragile histidine triad expression in colorectal cancer and its association with apoptosis inhibition. Cao J; Chen XP; Li WL; Xia J; Du H; Tang WB; Wang H; Chen XW; Xiao HQ; Li YY World J Gastroenterol; 2007 Feb; 13(7):1018-26. PubMed ID: 17373735 [TBL] [Abstract][Full Text] [Related]
30. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation. Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840 [TBL] [Abstract][Full Text] [Related]
31. Evaluation of Relationship between Occurrence of Liver Cancer and Methylation of Fragile Histidine Triad (FHIT) and P16 Genes. Bai Y; Shen Y; Yuan Q; Lv C; Xing Q Med Sci Monit; 2019 Feb; 25():1301-1306. PubMed ID: 30773529 [TBL] [Abstract][Full Text] [Related]
32. Association of the promoter methylation and protein expression of Fragile Histidine Triad (FHIT) gene with the progression of differentiated thyroid carcinoma. Yin DT; Wang L; Sun J; Yin F; Yan Q; Shen R; He G; Gao JX Int J Clin Exp Pathol; 2010 May; 3(5):482-91. PubMed ID: 20606729 [TBL] [Abstract][Full Text] [Related]
33. FHIT alterations in cancerous and non-cancerous cervical epithelium. Yoshino K; Enomoto T; Nakamura T; Sun H; Ozaki K; Nakashima R; Wada H; Saitoh J; Watanabe Y; Noda K; Murata Y Int J Cancer; 2000 Jan; 85(1):6-13. PubMed ID: 10585575 [TBL] [Abstract][Full Text] [Related]
34. Diagnostic value of the FHIT and p16 mRNA loss and the K-ras gene mutation in pleural fluids for malignant pleural effusion. Li J; Bao QL; Wang Y; Hu YM; Chen P Cancer Biomark; 2013; 13(1):49-58. PubMed ID: 23736021 [TBL] [Abstract][Full Text] [Related]
35. Loss of fragile histidine triad expression in colorectal carcinomas and premalignant lesions. Hao XP; Willis JE; Pretlow TG; Rao JS; MacLennan GT; Talbot IC; Pretlow TP Cancer Res; 2000 Jan; 60(1):18-21. PubMed ID: 10646844 [TBL] [Abstract][Full Text] [Related]
36. [Relationship between the reduction of FHIT expression and the development of cervical carcinoma]. Liu H; Peng ZL; Yang KX; Liu SL; Wang H; Zhang CS; Fan YJ; Zheng A Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Nov; 35(6):846-8. PubMed ID: 15573771 [TBL] [Abstract][Full Text] [Related]
37. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development. Lea JS; Ashfaq R; Muneer S; Burbee DG; Miller DS; Minna JD; Muller CY J Soc Gynecol Investig; 2004 Jul; 11(5):329-37. PubMed ID: 15219888 [TBL] [Abstract][Full Text] [Related]
38. Aberrant expression and deletion of FHIT gene in leukemias. Wang L; Dong LJ; Tian F; Liu GX; Li CH Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Apr; 11(2):153-60. PubMed ID: 12744737 [TBL] [Abstract][Full Text] [Related]
39. Epigenetic silencing contributes to frequent loss of the fragile histidine triad tumour suppressor in basal cell carcinomas. Goldberg M; Rummelt C; Laerm A; Helmbold P; Holbach LM; Ballhausen WG Br J Dermatol; 2006 Dec; 155(6):1154-8. PubMed ID: 17107382 [TBL] [Abstract][Full Text] [Related]
40. Assessment of the prognostic value of methylation status and expression levels of FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian patients. Haroun RA; Zakhary NI; Mohamed MR; Abdelrahman AM; Kandil EI; Shalaby KA Asian Pac J Cancer Prev; 2014; 15(10):4281-7. PubMed ID: 24935385 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]